Ligand-induced Desensitization of the Human CXC Chemokine Receptor-2 Is Modulated by Multiple Serine Residues in the Carboxyl-terminal Domain of the Receptor*

(Received for publication, April 30, 1996, and in revised form, January 21, 1997)

Susan G. Mueller Dagger , John R. White §, Wayne P. Schraw Dagger , Vinh Lam Dagger and Ann Richmond Dagger par

From the Dagger  Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2175, the  Veterans Affairs Medical Center, Nashville, Tennessee 37212-2637, and § SmithKline Beecham Pharmaceuticals, Department of Immunology, King of Prussia, Pennsylvania 19406-0939

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

We have characterized the ligand-enhanced phosphorylation of the CXC chemokine receptor-2 (CXCR2) in a series of clonal 3ASubE cell lines expressing receptors truncated or mutated in the carboxyl-terminal domain. Truncation of CXCR2 by substitution of a stop codon for Ser-342 (342T) or Ser-331 (331T) results in total loss of melanoma growth stimulatory activity/growth-related protein (MGSA/GRO)-enhanced receptor phosphorylation, which cannot be explained based upon altered ligand binding affinity or receptor number. 3ASubE cells expressing 342T or CXCR2 with mutation of Ser-342, -346, -347, and -348 to alanine (4A) exhibit strong mobilization of Ca2+ in response to ligand (interleukin-8 or MGSA/GRO), with a recovery phase significantly slower than that of cells expressing wild type (WT) CXCR2. In contrast to the WT CXCR2, which is 93% desensitized by 20 nM ligand, the 331T, 342T, and 4A CXCR2 mutants do not undergo significant ligand-induced desensitization, and respond to a second ligand challenge by mobilizing Ca2+. The 3ASubE cells expressing CXCR2 with mutation of Ser-346, -347, and -348 to alanine, or with mutation of only one serine in this domain, continue to be phosphorylated in response to ligand and are 60-70% desensitized following the initial ligand challenge. WT CXCR2 phosphorylation and desensitization occur in <1 min, while receptor sequestration is a much later event (30-60 min). However, mutant receptors that are neither phosphorylated nor desensitized in response to ligand are <10% sequestered 60 min following ligand challenge. These data demonstrate for the first time that ligand binding to CXCR2 results in receptor phosphorylation, desensitization, and sequestration and that serine residues 342 and 346-348 participate in the desensitization and sequestration processes.


INTRODUCTION

The CXC chemokine,1 IL-8, specifically binds the CXC chemokine receptor, CXCR1, while a second receptor, CXCR2, is shared by IL-8, MGSA/GRO, and several other CXC chemokines (1). In human neutrophils, a 10-min treatment with IL-8 induces the internalization of greater than 90% of the CXC chemokine receptors, CXCR1 and CXCR2 (2). Low MGSA/GRO concentrations (0.2 nM) down-regulated 50% of CXCR2 expressed on neutrophils, while 7-13-fold higher IL-8 concentrations are required to down-regulate 50% of CXCR1 (3). Cell surface expression of CXCR1 is 100% restored after 1.5 h, while only 40% of the initial CXCR2 expression can be detected after 3 h of incubation following ligand treatment (3). We have previously demonstrated in both 3ASubE and 293 stable transfectants expressing CXCR2 that ligand binding results in the phosphorylation of CXCR2 on serine residues (4, 5). Within 1 min after ligand binding, MGSA/GRO stimulates the phosphorylation of CXCR2, and after prolonged treatment with MGSA/GRO ~40% of the receptors are degraded (4). Phorbol ester treatment (100 nM for 2 h) of 3ASubE cells expressing CXCR2 also results in serine phosphorylation, down-regulation, and degradation of the receptor (5). These data suggest that phosphorylation of CXCR2 induces receptor internalization (sequestration) and degradation, as has been observed in certain adrenergic receptors (6-8). Recently, Ben-Baruch et al. (9) demonstrated that 293 cells expressing CXCR2 exhibiting a deletion of amino acids 317-355 from the carboxyl-terminal domain do not exhibit chemotaxis in response to IL-8 (9). Since ligand did induce migration of 293 cells expressing CXCR2 with a deletion of residues 325-355, residues 317-324 appear to be essential for signal transduction and chemotaxis in response to IL-8 (9).

In the present study, we show that CXCR2 mutants exhibiting a loss of residues 331-355 (331T) or 342-355 (342T) no longer undergo ligand-enhanced receptor phosphorylation or desensitization as monitored by Ca2+ mobilization in response to ligand challenge. In contrast, receptors exhibiting deletion of amino acid residues 352-355 (352T) continue to undergo phosphorylation in response to ligand. In an effort to determine which specific serine residues are phosphorylated, we mutated individual serine residues 342, 346, 347, and 348 to alanine (S342A, S346A, S347A, S348A) or groups of serine residues to alanine: 346/7/8 (3A) and 342/6/7/8 (4A). Studies with 3ASubE cells expressing these mutant receptors, as compared with 3ASubE cells expressing wild type CXCR2, revealed that serines 342, 346, 347, and 348 of CXCR2 are involved in the desensitization of the receptor to its ligand. However, when these serine residues are mutated to alanine (4A or 3A CXCR2), other serine residues in the carboxyl-terminal domain can be phosphorylated, and the receptor is partially desensitized in response to ligand. In 3ASubE cells, phosphorylation and desensitization of WT CXCR2 occurs within 1 min after ligand treatment, while receptor sequestration requires >30 min. The 342T CXCR2 receptor is not sequestered in response to ligand. These data demonstrate that for CXCR2, specific residues along the carboxyl-terminal domain of the receptor mediate receptor desensitization and sequestration in response to ligand.


EXPERIMENTAL PROCEDURES

Generation of Truncated CXCR2 Mutants

Polymerase chain reaction strategies were employed to generate truncated CXCR2 mutants with stop codons introduced at Ser-331, Ser-342, or Ser-352. Polymerase chain reaction was conducted on the cDNA encoding the entire open reading frame for the CXCR2, which had been subcloned into BlueScript. The primer pair for each reaction included a common primer for the 5' end of the open reading frame. Unique primers that would introduce the desired stop codons were used for the 3' end and were as follows: ser331(331T), GCGAAGCTTTTAGATCAAGCCATGTATAGC; ser342(342T), GCGAAGCTTTTAAGGCCTGCTGTCTTTGGG; and ser352(352T), GCGAAGCTTTTAAGTGTGCCCTGAAGAAGA. The polymerase chain reaction-generated fragments were isolated, subcloned into BlueScript, and sequenced. Once the sequences were shown to be correct, the cDNAs for the truncated receptors were subcloned into the mammalian expression vector pRc/CMV and subsequently transfected into the human placental cell line, 3ASubE, or human embryonic kidney 293 cells.

Site-directed Mutagenesis of the CXCR2

Mutagenesis of specific serine to alanine (Ser right-arrow Ala) residues was conducted using the pALTER site-directed mutagenesis system (Promega). The following mutations were synthesized using the indicated primers: ser342ala(S342A), AGACAGCAGGCCGGCCTTTGTTGGC; ser346ala(S346A), TCCTTTGTTGGCGCCTCTTCAGGGCAC; ser347ala(S347A), CTTTGTTGGCTCAGCTTCAGGGCACA; ser348ala(S348A), GTTGGCTCTTCTGCCGGGCACACTTCC; ser346/7/8ala(3A), TCCTTTGTTGGCGCCGCTGCAGGGCACACTT. Receptor mutants were screened by restriction analysis and then sequenced. The Ser-346/347/348 right-arrow Ala mutant was used as a template with the ser342ala primer to generate a Ser-342/346/347/348 right-arrow Ala (4A) mutant. Once the mutations were confirmed, the cDNAs encoding the open reading frame for the CXCR2 mutants were subcloned into the pRc/CMV expression vector and transfected into the 3ASubE cell line or human embryonic kidney 293 cells.

Generation of Stable Transfectants

Immortalized human 3ASubE placental cells were maintained in 5% fetal bovine serum (FBS)/Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Inc.), and human embryonic kidney 293 cells were maintained in 7.5% FBS/DMEM as described previously (4). Clonally selected, stable 3ASubE transfectants were generated for the truncated receptor mutants as described previously (4). The stable transfectants expressing CXCR2 mutations were selected based upon expression of immunoreactive CXCR2 using antibody to the NH2 terminus of CXCR2 in an indirect immunohistochemical staining protocol. Stable 3ASubE transfectants identified as expressing immunoreactive receptor at the plasma membrane in this screen were analyzed for 125I-MGSA binding activity using our standard binding assay (4). Clones of stable transfectants were generated that bind 125I-MGSA/GRO 3-5-fold above background levels, where the background cpm are calculated as the 125I-MGSA/GRO bound in the presence of 128 ng/ml unlabeled MGSA/GRO (16 nM). Two clones with strong ligand-binding properties were selected for each mutation and analyzed for ligand binding affinity and ligand-induced receptor phosphorylation. One representative clone of each of the mutants analyzed for ligand binding and phosphorylation was selected for analysis of ligand-induced calcium mobilization. Both 3ASubE and 293 clones expressing WT and 342T CXCR2 were analyzed for ligand-induced receptor sequestration. Chemotaxis studies were performed with 293 cells expressing WT or 342T CXCR2, since 3ASubE cells expressing CXCR2 did not undergo MGSA/GRO-induced chemotaxis.

125I-MGSA/GRO Binding Assay

MGSA/GRO (1 µg), generously provided by R + D Systems and Repligen Corporation, was iodinated using the chloramine T method, yielding a specific activity of ~100 µCi/µg, assuming 100% recovery. For most of the experiments reported here, 125I-MGSA/GRO was purchased from DuPont NEN at a specific activity of 272 µCi/µg. Binding assays were performed on stable transfectants as described previously (4). Each assay was repeated a minimum of two times with n = 3 for each of the representative clones.

In Vivo Phosphorylation Assay

In vivo phosphorylation and receptor immunoprecipitation assays were performed as described previously (4). Briefly, [32P]orthophosphate-labeled cells were then treated with MGSA/GRO (5 nM), 12-O-tetradecanoylphorbol-13-acetate (TPA) (400 nM), or vehicle alone for 10 min at 37 °C. Whole cell lysates were prepared, and the CXCR2 was immunoprecipitated from an equal number of trichloroacetic acid-precipitable counts (5 × 106 cpm), electrophoresed through a 9% SDS-polyacrylamide gel, which was subsequently dried and analyzed by autoradiography (Imaging film, BioMax MR, Eastman Kodak Co.), or transblotted onto nitrocellulose for autoradiography and immunodetection. Each assay was repeated at least twice, and the phosphorylation was quantitated by PhosphorImage analysis (Molecular Dynamics) or densitometric scanning.

Western Blot Analysis

Transblotted membranes were blocked for 1 h at room temperature in 5% milk powder/Tris-buffered saline, incubated overnight with affinity-purified anti-NH2-terminal peptide antibody to CXCR2 (2 µg/ml) in 5% milk powder/Tris-buffered saline and then developed as described previously (4).

Receptor Degradation Studies

Confluent cultures (60-mm dishes) of the 3ASubE transfectants were placed in serum-free DMEM and treated with MGSA (50 nM), TPA (400 nM), or the appropriate vehicle control for 2 h at 37 °C. For some experiments, serum-starved cells were treated with 25 nM MGSA/GRO for 1-6 h. Plates were rinsed on ice with Tris-buffered saline and then scraped in 300 µl of Triton X-100 lysis buffer as described previously (5). The cell lysates were clarified by centrifugation at 15,000 × g at 4 °C for 15 min, the supernatants were transferred to a fresh tube, and protein estimates were performed (BCA, Pierce). Twenty-five micrograms of protein were loaded per lane on a 9% SDS-polyacrylamide gel, electrophoresed, transblotted onto a nitrocellulose membrane, and analyzed as described above.

Calcium Fluorimetry

Transfected 3ASubE cells expressing truncation and Ser right-arrow Ala mutants were grown until confluent. Cells were released by a short exposure (1-2 min) to Versine (trypsin/EDTA) and washed once in culture medium containing 5% FBS. Cells were then washed a second time in Krebs-Ringer solution (118 mM NaCl, 4.56 mM KCl, 25 mM NaHCO3, 1.03 mM KH2PO4, 11.1 mM glucose, 5 mM HEPES) without Ca2+ or Mg2+. Cells were resuspended at 2 × 106 cells/ml and incubated with FURA-2 for 30 min (2 µM final concentration). After 30 min, the volume of buffer was doubled with the Krebs-Ringer solution (without Ca2+ and Mg2+), and the cells were incubated for 10 min. Cells were then centrifuged (300 × g, 6 min) and washed once (50 ml) in Krebs-Ringer solution containing Ca2+ and Mg2+ (1 mM). The cells were finally adjusted to 1 × 106 cells/ml. Ca2+ mobilization experiments were performed using a single scanning spectrofluorimeter constructed by the University of Pennsylvania Department of Bioengineering. Data were collected using an IBM model PS-II computer with custom written software provided by the Department of Laboratory Automation, SmithKline Beecham. Data were analyzed using the software program, Igor, which used the following equation to determine free Ca2+.
<UP>Ca<SUP>2+</SUP> n<SC>m</SC> = 244 × </UP><FR><NU>(F <UP>− </UP>F<SUB><UP>min</UP></SUB>)</NU><DE>(F<SUB><UP>max</UP></SUB><UP> </UP>−F)</DE></FR> (Eq. 1)
Fmax is the maximum fluorescence (in the presence of 1 mM free Ca2+), and Fmin is the minimum fluorescence in the presence of EGTA (5 mM). The constant, 224, is the dissociation (Kd) constant between FURA-2 and Ca2+. Generally, cells (2 ml) were allowed to reach 37 °C for 5 min prior to stimulation with MGSA/GRO (Peprotech) or IL-8 at the indicated concentration. The fluorescence was monitored continually for the specified time. Since none of the clones reached prestimulatory levels of Ca2+ within the time frame of the experiment (5 min), the time taken to remove 80% of the mobilized Ca2+ was used as a measure of Ca2+ removal (t80). For the purpose of comparison, a dose response was first performed to determine the concentration of ligand that would provide similar Ca2+ mobilization in each of the clones. Based upon these results, clones expressing WT, 331T, 342T, 4A, and S342A CXCR2 were stimulated with IL-8 concentrations of 5-10, 0.33-1, 0.33-1, 1-3.3, and 3.3-10 nM, respectively. Because of the variability between experiments and the requirement to compare each clone with a similar Ca2+ mobilization, the concentration of IL-8 used to achieve that Ca2+ change is given as a range. The data were analyzed by the Kruskall-Wallis test and the paired Student's t test.

In the desensitization experiments, cells (6 ml total, at 1 × 106 cells/ml, 37 °C) were stimulated with 20 nM MGSA/GRO, IL-8 (stimulated), or buffer (control) for 5 min before being washed three times with 15 ml of Krebs-Ringer buffer with Ca2+ and Mg2+ (1 mM). Cells were finally resuspended at (1 × 106 cells/ml) and kept on ice until needed. Cells were allowed to warm to 37 °C for 5 min before the second stimulus of IL-8 or MGSA/GRO (5 nM) as described previously. The data were analyzed by both the paired Student's t test and the Kruskall-Wallis test. To measure the time course of desensitization, clones expressing wild type and the 342T CXCR2 were stimulated with MGSA/GRO or IL-8 (20 nM) for 30 s to 30 min before being washed, resuspended, and stimulated with a second concentration of IL-8 (5 nM), and the maximum Ca2+ mobilization was calculated. The data were analyzed by the Wilcoxon rank-sum test.

Effects of Mutation of Carboxyl Terminus of CXCR2 on Receptor Sequestration

To compare the time course of internalization of the wild type CXCR2 receptor to that of the 342T mutant CXCR2 (4), confluent, serum-starved 3ASubE cells expressing WT or 342T CXCR2 were pretreated with saturating concentrations of MGSA/GRO or IL-8 (100 nM) for 1, 5, 15, 30, or 60 min at 37 °C. Free ligand was removed with three ice-cold (0.5 ml) washes of binding buffer (1 mg/ml ovalbumin in DMEM), and the receptor remaining at the cell surface was monitored by indirect immunodetection. Briefly, the cells were incubated with 2 µg of antibody to the NH2 terminus of CXCR2 in 250 µl of binding buffer for 2 h at 4 °C, excess antibody was removed by washing with 1 ml of binding buffer at 4 °C, and then 250 µl of 125I-labeled goat anti-rabbit IgG (2 × 105 cpm, specific activity 300 µCi/ml) was added and incubated for 30 min at 4 °C. Excess antibody was then aspirated; cells were washed twice with 1 ml of binding buffer at 4 °C, lysed in 0.5 ml of lysis buffer (1% SDS, 0.1 N NaOH); and radioactivity determinations were made by gamma  counting. Nonspecific binding was estimated by preblocking the NH2-terminal antibody with a 20-fold molar excess of peptide to which the antibody was generated before adding the antibody to the cells. The data exhibited a normal distribution and were analyzed by the paired t test as well as by the nonparametric Wilcoxon rank-sum test.

Chemotaxis Assay

Chemotaxis assays were performed on 293 cells expressing WT or mutant CXCR2 according to the protocols of Ben-Baruch et al. (9) with modification. The 96-well chemotaxis chamber (Neuroprobe Inc., Cabin John, MD) was used, and the lower compartment of the chamber was loaded with 360-µl aliquots of 1 mg/ml ovalbumin/DMEM or MGSA/GRO diluted in ovalbumin/DMEM (chemotaxis buffer). The polycarbonate membrane (10-µm pore size) was coated on both sides with 20 µg/ml human collagen type IV for 2 h at 37 °C and stored overnight at 4 °C. The cells were removed by trypsinization and incubated in 10% FBS/DMEM for 1.5 h at 37 °C to allow restoration of receptor, washed in chemotaxis buffer, and then placed into the upper chamber in the ovalbumin medium. The chambers were incubated for 4.5-6 h at 37 °C in humidified air with 5% CO2, and then the filter was removed, washed, fixed, and stained with a Diff-Quik kit. Quantitation of relative chemotaxis indices was by densitometric scanning of the stained filter. Briefly, the filter was scanned using a Epson ES 1200C densitometric scanner and the Adobe Photoshop software. Digitized images were subsequently scanned using the Molecular Dynamics PhosphorImager. Volumes were integrated and normalized to a value of 1 for the control of each set.


RESULTS

Effects of Serine Mutation on Ligand-induced CXCR2 Phosphorylation

We have previously demonstrated that the CXCR2 expressed in nonhematopoietic cells is phosphorylated on serine residue(s) in response to either MGSA/GRO or phorbol ester treatment in a time- and concentration-dependent manner (4, 5). There are eight serine residues within the carboxyl-terminal domain of CXCR2 that may serve as potential phosphorylation sites (Table I). As an initial attempt to localize the site(s) of serine phosphorylation on this receptor, truncated receptors were generated by introducing stop codons at Ser-331, -342, and -352. These truncations were designed to remove all eight serine residues from the carboxyl-terminal domain, the final five serine residues, or the final serine residue, respectively. The truncated receptor constructs were subcloned into the pRc/CMV mammalian expression vector and transfected into the human placental 3ASubE cell line or the human embryonic kidney 293 cell line. Neither of these cells naturally expresses CXCR2 or exhibits specific binding for 125I-MGSA/GRO (9).

Table I.

Design of mutations of the carboxyl terminus of CXCR2

The serine residues in the carboxyl terminus of the receptor that were mutated to alanine are as shown.


WT330 T S K D S L P K D S R P S F V G S S S G H T S T T L355
331T T
342T T S K D S L P K D S R P
352T T S K D S L P K D S R P S F V G S S S G H T
3A T S K D S L P K D S R P S F V G A A A G H T S T T L
4A T S K D S L P K D S R P A F V G A A A G H T S T T L
S342A T S K D S L P K D S R P A F V G S S S G H T S T T L
S346A T S K D S L P K D S R P S F V G A S S G H T S T T L
S347A T S K D S L P K D S R P S F V G S A S G H T S T T L
S348A T S K D S L P K D S R P S F V G S S A G H T S T T L

Selected clones of 3ASubE cells, expressing the WT CXCR2 or various truncated forms of CXCR2, were characterized for ligand binding and ligand-induced receptor phosphorylation. Clones were also analyzed to determine whether these receptors are phosphorylated in response to TPA, an activator of protein kinase C. As demonstrated in Fig. 1, both the wild-type CXCR2 and the 352T receptor were phosphorylated in response to 10-min treatment with either MGSA/GRO (5 nM) or TPA (400 nM), while the 331T and 342T receptors were not phosphorylated in response to either of these treatments (Fig. 1). In contrast, the binding of 125I-MGSA/GRO was not impaired in the 3ASubE cells expressing CXCR2 truncation mutants relative to cells expressing WT CXCR2 (data not shown). Western blot analysis of the immunoprecipitates indicated that approximately equal amounts of CXCR2 protein were immunoprecipitated from the treated and untreated samples (data not shown). Similar observations were made when the in vivo phosphorylation assay was conducted using higher concentrations of MGSA/GRO (50 nM) (data not shown). These results suggested that the potential sites of receptor phosphorylation include serine residues at position 342, 346, 347, and/or 348. 


Fig. 1. MGSA and TPA induce phosphorylation of WT and 352T CXCR2 but not the truncation mutants 331T and 342T CXCR2. 3ASubE clones expressing WT and mutant CXCR2 were labeled with [32P]orthophosphate as described under "Experimental Procedures" and treated in the absence or presence of MGSA (5 nM) or TPA (400 nM) for 10 min at 37°C. Whole cell lysates were prepared, and CXCR2 was immunoprecipitated from an equal number of trichloroacetic acid-precipitable counts (5 × 106 cpm), using 5 µg of affinity-purified anti-NH2-terminal polyclonal antibodies followed by protein A/G-agarose. Immunoprecipitates were electrophoresed through a 9% SDS-polyacrylamide gel, the gel was dried and exposed to imaging film for autoradiographic analysis. Experiments were repeated twice with similar results each time. The lower band represents the phosphorylated CXCR2.
[View Larger Version of this Image (35K GIF file)]


Effects of Ser right-arrow Ala Mutagenesis on Ligand-induced Receptor Phosphorylation in 3ASubE Cells

Serine to alanine mutations were then made at individual serine residues (Ser-342 right-arrow Ala (S342A), Ser-346 right-arrow Ala (S346A), Ser-347 right-arrow ala (S347A), Ser-348 right-arrow Ala (S348A)) and at multiple serine residues (Ser-346, -347, and -348 (3A) or Ser-342, -346, -347, and -348 (4A)) (Table I). Stable 3ASubE transfectants expressing these Ser/Ala mutations were generated. These clones were characterized with regard to MGSA/GRO binding and MGSA/GRO ligand-induced receptor phosphorylation. Four clones expressing CXCR2 exhibited reduced basal receptor phosphorylation as compared with WT: 4A, S342A, S346A, and S348A (Fig. 2 and Table II). The ligand-induced phosphorylation was diminished 25-75% in the clones expressing mutant receptor (Table II). However, when these data were normalized to receptor number, we found that the ligand-induced receptor phosphorylation in the mutant clones was comparable with that of clones expressing the WT receptor (Table II). The ligand dissociation constant (Kd) for each mutant and WT CXCR2 was in the 2-4 nM range (Table II). These results suggested that multiple serine residues were phosphorylated in response to MGSA/GRO, and altering individual serine residues did not eliminate ligand-induced receptor phosphorylation. Replacement of as many as four of the serine residues with alanine (4A) did not diminish the overall -fold increase for ligand-induction of phosphorylation. (Table II and Fig. 2). Similar results were observed for the two different 4A mutant clones studied. Thus, mutation of the serine residues, which are the apparent natural substrates for the ligand-activated serine kinase for CXCR2, did not eliminate ligand-induced receptor phosphorylation.


Fig. 2. MGSA-induced phosphorylation of serine to alanine mutants of CXCR2. Confluent, serum-starved 3ASubE cells expressing the various CXCR2 serine to alanine mutations were metabolically labeled with [32P]orthophosphate and stimulated with 25 nM MGSA or vehicle (10 min, 37 °C), and whole cell lysates were prepared as described under "Experimental Procedures." Equal amounts of trichloroacetic acid-precipitable counts (5 × 106 cpm) of each clone were immunoprecipitated with 5 µg anti-CXCR2 anti-NH2-terminal peptide affinity-purified polyclonal antibody followed by protein A/G-agarose. Immunoprecipitates were subjected to SDS-polyacrylamide gel electrophoresis, and the gel was dried and exposed to film for autoradiography. The data shown are representative of 2-6 independent experiments from the various clones, and the standard deviations of the -fold increase in the phosphorylation in response to ligand are listed in Table II. CXCR2 is designated at the arrow. The upper band is nonspecific.
[View Larger Version of this Image (28K GIF file)]


Table II.

Quantitation of the phosphorylation of WT and serine to alanine mutant CXCR2 in response to MGSA

Clones of 3ASubE cells expressing WT or mutant CXCR2 were characterized for ligand binding and based upon Scatchard analysis of the data; the Kd and number of expressed receptors were calculated from two separate experiments performed in triplicate. Confluent, serum-starved cultures of these cells were treated with MGSA/GRO as described in Fig. 2, and phosphorylation was quantitated by PhosphorImage analyses. The data indicated represent the means from 2-6 individual experiments. Two-clones of the 3A, 4A, S346A, and S347A mutants were studied, and the means of those two clones are indicated. The S348A and S342A results shown are the means of two and three individual experiments on a single clone, respectively. The -fold phosphorylation over that of basal and the -fold induction normalized to receptors/cell are shown for those experiments. Scatchard analysis of ligand binding on 3ASubE clones expressing WT and mutant CXCR2 was performed as described under "Experimental Procedures." Three replicates were used at each ligand concentration and the experiments were repeated at least twice. The standard deviation of the replicates ranged from 1 to 6% of the mean, and the LIGAND program was used for ligand binding analysis as previously described (4).


Clone Receptors/cell × 105 (range) Kd (range) Mean basal phosphorylation n MGSA-stimulated phosphorylation/basal -Fold induction/receptors per cell

WT 6.7  (9.7-3.6) 3.4  (3.2-3.5) 1.00 3 11.6  ± 1.5 1.7
3A 2.6  (1.8-3.4) 3.7  (3.5-4.0) 1.64 4 5.8  ± 0.8 2.2
4A 0.6  (0.8-0.5) 3.0  (2.8-3.2) 0.68 6 3.2  ± 0.9 5.3
S342A 4.3  (4.5-4.0) 3.5  (2.2-4.8) 0.79 3 6.4  ± 0.8 1.5
S346A 2.4  (2.4-2.3) 1.9  (1.8-2.0) 0.80 3 5.7  ± 2.0 2.4
S347A 3.0  (3.3-2.8) 2.5  (2.2-2.8) 1.00 4 7.4  ± 0.70 2.5
S348A 2.8  (4.1-1.5) 2.4  (2.0-2.7) 0.73 2 8.45  (8.4-8.5) 3.0

Effects of Receptor Truncation on Receptor Degradation

In 3ASubE cells, phorbol ester-induced phosphorylation of CXCR2 has been demonstrated to be accompanied by receptor down-regulation and degradation (5). MGSA/GRO treatment (50 nM for 2 h) of 3ASubE cells expressing WT CXCR2 also resulted in phosphorylation and partial degradation of the receptor (5). As an initial approach to determine whether receptor phosphorylation is required for receptor degradation in response to these stimuli, the effect of MGSA/GRO (50 nM) or TPA treatment (400 nM) for 2 h at 37 °C on the degradation of 331T, 342T, and 352T CXCR2 was examined in 3ASubE cells. As we have previously demonstrated, Western blot analysis of the lysates prepared from TPA-treated 3ASubE cells expressing WT CXCR2 revealed that continuous TPA treatment resulted in a significant decrease in immunoreactive CXCR2. MGSA/GRO or TPA treatment of the 3ASubE cells expressing 352T also decreased CXCR2 protein. Neither MGSA/GRO nor TPA treatment of 3ASubE clones expressing 331T or 342T produced a decrease in CXCR2 protein (Fig. 3A). In response to MGSA/GRO, the reduction in CXCR2 was less striking, although all of the receptor exhibited the reduced electrophoretic mobility that is indicative of the phosphorylated form of the receptor (Fig. 3A). However, MGSA/GRO treatment (25 nM for 6 h) of 3ASubE cells expressing WT CXCR2 produces a ~50% diminution in the immunoreactive CXCR2 (Fig. 3B). Thus, the carboxyl-terminal domain of CXCR2 appears to be required for the receptor degradation that usually accompanies ligand-induced receptor phosphorylation. Furthermore, the degradation of CXCR2 that occurs in response to TPA is more extensive than that which occurs in response to MGSA/GRO (Fig. 3A).


Fig. 3. Effect of MGSA or TPA treatment on CXCR2 phosphorylation and degradation. A, confluent cultures of 3ASubE P-3 clones expressing WT or mutant CXCR2 were stimulated with MGSA (50 nM), TPA (400 nM), or vehicle alone for 2 h at 37 °C. 25 µg of protein from clarified Triton X-100 lysates were loaded per lane and electrophoresed through a 9% SDS-polyacrylamide gel, and Western blot analysis was performed with polyclonal antibody to NH2-terminal CXCR2 and visualized by alkaline phosphatase-conjugated secondary antibody as described under "Experimental Procedures." A, vehicle alone; M, MGSA treatment; T, TPA treatment. B, confluent cultures of 3ASubE P-3 cells expressing wild type CXCR2 were exposed to MGSA/GRO (25 nM) for the time periods indicated as described under "Experimental Procedures" and analyzed by Western blot to determine the receptor degradation over time with treatment of saturating concentrations of ligand. The density of the bands representing CXCR2 were determined by densitometric scanning for three independent experiments, and the quantitation of these scans is shown in the histogram as mean ± S.D.
[View Larger Version of this Image (28K GIF file)]


Effects of Ser right-arrow Ala Mutation of CXCR2 on Ligand-induced Calcium Mobilization in 3ASubE Cells

To determine the requirement for serine phosphorylation in signal transduction, Ca2+ mobilization and desensitization were investigated in 3ASubE clones expressing WT and mutant CXCR2. All 3ASubE clones studied mobilized Ca2+ in response to IL-8 comparable with that observed in neutrophils or differentiated HL60 cells (EC50, 2-5 nM), except that the maximum Ca2+ response was diminished in magnitude. The transfected 3ASubE cells expressing WT CXCR2 responded to IL-8 (5 nM) with an increase in intracellular Ca2+, which peaked approximately 25 s following agonist addition (Fig. 4). The level of intracellular Ca2+ returned to base line rapidly. 3ASubE clones expressing 331T or 4A CXCR2 exhibited a markedly slower removal of ligand mobilized Ca2+ with a t80 of 179 and 135 s, respectively, while the clone expressing WT CXCR2 required only 71 s to remove the mobilized Ca2+ (Fig. 4 and Table III). These data suggest that serines 342-, 346-, 347-, and 348- participate in the regulation of Ca2+ homeostasis. 3ASubE clones expressing S342A CXCR2 exhibited removal of Ca2+, which was not significantly different from the WT. Since intracellular Ca2+ as determined by FURA-2 in the presence or absence of EGTA (5 mM) has both a component of influx and efflux (data not shown), we cannot rule out the possibility that the various mutants differ in the removal of influxed versus effluxed Ca2+.


Fig. 4. Time course of Ca2+ mobilization in 3ASubE cells expressing WT and mutant CXCR2. 3ASubE cells expressing WT, 331T, or 4A CXCR2 were loaded with FURA-2, stimulated with IL-8, and analyzed for ability to release Ca2+ from intracellular stores according to the protocols described under "Experimental Procedures." To compare the time course for removal of Ca2+ mobilized in response to ligand, each of the clones was stimulated with a concentration of ligand that would result in similar maximum of Ca2+ mobilization, and the fluorescence was monitored for 180-210 s. The clones expressing WT, 331T, and 4A CXCR2 were stimulated with 5.0, 0.33, and 0.33 nM IL-8, respectively. This figure shows a representative experiment. Each of the clones was studied six times, with the variability described in Table IV. Sec, seconds.
[View Larger Version of this Image (21K GIF file)]


Table III.

Effect of mutation of the COOH-terminal domain of CXCR2 on Ca2+ Mobilization and Ligand-induced receptor desensitization

The time required for each of the 3ASubE clones stimulated with IL-8 to remove 80% of the influxed Ca2+ is shown in the second column as t0.8 ± S.E. For the t0.8 values, in order to get similar Ca2+ mobilization in each of the clones for comparison purposes, concentrations required for equivalent response were determined, and based upon these data clones were stimulated with ligand at the optimal concentrations as described under "Experimental Procedures." The change in Ca2+ from resting levels to maximum was calculated, and then the time to remove 80% of the influxed Ca2+ was derived from each curve. The third column shows the desensitization of the various clones of 3ASubE cells induced by prior exposure to IL-8 (20 nM), followed by a second stimulation with a lower concentration of IL-8 (5nM). The numbers in the third column represent the percentage of the control response following the second exposure to IL-8 when each clone was stimulated with IL-8 (5 nM) and the increase in fluorescence was monitored continually. This table represents the mean time in seconds (s) ± S.E. from three separate experiments. Where noted, p values are based upon the Kruskall-Wallis test.


Clone name t0.8 ± S.E. Percentage of control response remaining after desensitization ± S.E.

s %
WT 71.0  ± 10.0 7.1  ± 2.8
331T 179.0  ± 34.7a,b 97.1  ± 11.7c
342T 115.0  ± 18.4c 100.8  ± 9.9d
4A 135.0  ± 18.1d 79.1  ± 5.1c
3A NDe 39.4  ± 7.5c
S342A 98.0  ± 16.8a 28.0  ± 3.0c
S346A ND 33.6  ± 1.7d
S347A ND 30.1  ± 7.2c

a Not significant.
b p value based upon t test, p < 0.02.
c p < 0.01.
d p < 0.05.
e ND, not determined.

To determine if mutation or truncation of the receptor was associated with desensitization to ligand, FURA-2-loaded clones were stimulated with buffer, 20 nM IL-8, or 20 nM MGSA/GRO. Ligand was removed by repeated washing, and the clones were treated a second time with a lower concentration (5 nM) of either MGSA/GRO or IL-8. As expected, WT clones were substantially desensitized by the first addition of IL-8, with the second addition (noted by the arrow on the chart) promoting a Ca2+ mobilization response that was only 7.1% of the original response (Fig. 5, A and B). In contrast, the clones expressing the 342T- (Fig. 5, C and D) and 331T (Table III) truncation mutants failed to be desensitized by the high concentration of ligand (p < 0.05) and exhibited a second response to ligand that was equivalent to the original response (Fig. 5 and Table III). Clones expressing the 4A mutant of CXCR2 exhibited a second calcium response, which was 79% of the initial response (only 21% desensitization). The clones expressing the 3A mutant or the single Ser right-arrow Ala mutants were 60-70% desensitized (Fig. 5, E and F, and Table III). These data strongly suggest that the residues beyond Ser-342 are responsible for desensitization of the receptor to its ligand, and serine residues 342, 346, 347, and 348 appear to be involved. Statistical analysis of the data comparing ligand-induced desensitization of mutant CXCR2 with WT CXCR2 demonstrated the mutant clones were significantly different from WT in their desensitization properties (Table III).


Fig. 5. Measurement of receptor desensitization in 3ASubE clones expressing WT and mutant CXCR2. Panels A, C, and E represent the Ca2+ mobilization (nM) induced by 5 nM IL-8 or 5 nM MGSA in 3ASubE cells expressing WT and mutant CXCR2. A, WT CXCR2; C, 342T CXCR2; E, 4A CXCR2. B, D, and F represent the same clones, first stimulated by IL-8 (20 nM), washed as described under "Experimental Procedures" and then stimulated by 5 nM IL-8 (arrow). The increase in FURA-2 fluorescence was monitored for a further 20-30 s, and the maximum Ca2+ mobilized was calculated. Each panel shows a representative experiment, and each experiment was repeated a minimum of three times. The variability and statistical analysis of the data from these experiments are summarized in Table III. Sec, seconds.
[View Larger Version of this Image (26K GIF file)]


For comparison, 3ASubE cells expressing WT and 342T CXCR2 were treated with 20 nM MGSA/GROalpha for 5 min, and then cells were washed and then warmed and stimulated with a second concentration of MGSA/GROalpha (5 nM) as described under "Experimental Procedures." The experiment was performed in triplicate. The percentage of response remaining with the second stimulus of MGSA/GRO (WT CXCR2, 18.3%; 342T CXCR2, 79.8%) was not remarkably different from that which occurred in response to IL-8 (WT CXCR2, 7.1%; 342T CXCR2, 100.8%)

Effects of Mutation of the Carboxyl-terminal Domain of CXCR2 on the Time Course of Receptor Desensitization and Sequestration

To compare the time course of desensitization of the WT CXCR2 to that of the 342T CXCR2, we examined the time required for recovery following ligand induction of CXCR2 desensitization in 3ASubE clones expressing these receptors. Desensitization of WT CXCR2 occurred within 1 min after ligand treatment and remained >70% desensitized after 30 min. In contrast, the 342T CXCR2 underwent only 18.5% desensitization by 5 min and was almost fully recovered after 30 min. (Table IV). To determine whether desensitization occurred as a result of receptor internalization, we monitored the time course for CXCR2 sequestration in 3ASubE cells expressing mutant or WT CXCR2. After a 15-min incubation with saturating concentrations of ligand (37 °C), approximately 25% of the WT receptors were sequestered (Table V). By 30 min, approximately 30% of the WT receptors were sequestered, and by 60 min, 33% were sequestered (Table V). IL-8 was about 10-15% more efficient than MGSA/GRO in the WT receptor sequestration assay, p < 0.01 (Table V). In contrast, for 3ASubE cells expressing the 342T mutant, nearly 100% of the immunoreactive receptor remained at the membrane after treatment with saturating concentrations of ligand for up to 30 min. At 60 min, 92% of the receptor remained at the membrane (Table V). IL-8 was not more efficient than MGSA/GRO in sequestering 342T CXCR2 in 3ASubE cells. (Table V). This was the expected result, based upon the failure of these receptors to phosphorylate or desensitize in response to ligand. The failure to sequester 100% of CXCR2 was probably due to the dynamics of the display of receptors at the cell membrane at 37 °C, where new receptors would be cycling to the membrane to replace those that were sequestered.

Table IV.

Time course for recovery of ligand induction of Ca2+ mobilization response in 3ASubE cells expressing WT and 342T CXCR2

Cells were loaded with Fura-2 as described under "Experimental Procedures." For each time point, each clone was stimulated with 20 nM IL-8 for the time indicated before the reaction was terminated by the addition of ice-cold buffer (PBS containing CaMg). Cells were washed three times in order to remove IL-8 and then individually stimulated with 5 nM IL-8, and the maximum Ca mobilized was determined. The table below shows the percentage of the original response (t = 0) remaining at each time point. The experiment was performed three times independently with n = 3 for each experiment per time point and for each clone. The percentage of response represents the mean from the six determinations ± S.E. Statistical analysis (Wilcoxon rank-sum test) of the data collected for each of the time points for the 342T CXCR2 as compared with WT CXCR2 revealed a p < 0.05 for the 0.5-, 1-, 15-, and 30-min time points and p < 0.1 for the 5-min point.


Percentage of control response
Time Wild type ± S.E. 342T ± S.E.

0 min 100 100
0.5 min 16.4  ± 6.4 100  ± 10.2
1 min 11.6  ± 0.3 83  ± 5.1
5 min 14.4  ± 7.0 81.5  ± 7.7
15 min 11.7  ± 1.69 79  ± 25
30 min 19.3  ± 9.3 80  ± 23

Table V.

Influence of MGSA/GRO versus IL-8 on WT and 342T CXCR2 down-regulation in 3ASubE cells

The time courses for MGSA/GRO- and IL-8-induced sequestration of WT or 342T CXCR2 in 3ASubE cells are shown. Cells expressing transfected receptor were pretreated with 100 nM ligand or vehicle for the time course indicated and then receptor presentation at the cell surface was monitored as described under "Experimental Procedures." The experiment was repeated three times in triplicate and one time in duplicate, with similar results each time. The variability of the triplicate samples for any time point was less than 5%. The values reported for the wild type receptor are the mean of the four independent experiments ± the S.D. and statistical analysis of the two sets of data by the paired t test indicated that the differences between MGSA/GRO and IL-8 were significant at the p < 0.01 level. The values reported for the 342T receptor are the means of two independent experiments in triplicate, and the experimental variability ranged from 3 to 9%.


Time of incubation with ligand Wild type CXCR2 percentage of receptor remaining
342T CXCR2 percentage of receptor remaining
MGSA/GRO treatment IL-8 treatment MGSA/GRO treatment IL-8 treatment

% % % %
1 min 97  ± 3% 88  ± 3 104 96.5
5 min 88  ± 10% 74  ± 4 88 81.7
15 min 76  ± 6% 63  ± 8 92 98.7
30 min 69  ± 2% 56  ± 4 95 94.3
60 min 67  ± 5% 52  ± 5 92 94.1

MGSA/GRO-induced Chemotaxis of 293 Cells Expressing WT and 342T CXCR2

To determine whether loss of ligand-induced CXCR2 phosphorylation, desensitization, and sequestration resulted in a chemokine receptor that exhibited loss of function, we examined the ability of 293 cells and 3ASubE cells expressing WT and 342T CXCR2 to chemotax toward a gradient of MGSA/GRO. We did not observe chemotaxis in response to MGSA/GRO in the 3ASubE cells expressing WT or 342T CXCR2 using filters coated with collagen type I, fibronectin, or Matrigel or filters with no coating (data not shown). However, 293 cells expressing both WT and 342T CXCR2 exhibited chemotaxis toward MGSA/GRO, and the cells expressing 342T CXCR2 showed a chemotaxis response that at the higher concentrations (40 ng/ml) was equivalent to that of cells expressing WT CXCR2 (data not shown). Thus, disruption of the carboxyl-terminal domain of CXCR2 involved in phosphorylation, desensitization, and sequestration, does not ablate the chemotactic functions of this receptor.


DISCUSSION

There is now considerable evidence that ligand binding to transmembrane-spanning receptors stimulates receptor phosphorylation on the carboxyl-terminal domain of the receptor and that this event coincides with receptor desensitization, sequestration, and in some instances degradation or recycling (3-8). Both CC and CXC chemokine receptors are phosphorylated in response to ligand binding, and multiple serine or serine and threonine residues are phosphorylated (4, 10, 11). Richardson et al. (11) have shown that the phosphorylation of CXCR1 is accompanied by receptor desensitization. CXCR2 expressed in CHO cells is reported to be internalized more rapidly than CXCR1, and MGSA induces this internalization more slowly than does IL-8 (12). Moreover, truncation of CXCR1 eliminates ~60% of the ligand-induced internalization of the receptor (12). In contrast, neutrophil CXCR1 and CXCR2 are both rapidly down-modulated by ligand (5 min), although considerably more ligand is required to down-modulate CXCR1 than CXCR2 (3). CXCR2 recycles more slowly than the CXCR1; moreover, only about 40% of the CXCR2 recycles during a 3-h culture period (3), while CXCR1 fully recovers 1.5 h after treatment with the IL-8 ligand in neutrophils. Our studies with 3ASubE cells show that desensitization and phosphorylation of WT CXCR2 occurs within 30-60 s after ligand treatment, while sequestration occurs much more slowly, requiring 30-60 min. Thus, CXCR2 clearance in 3ASubE cells is different from that reported for CHO cells (12). We have also observed that after 6 h of treatment with 25 nM MGSA/GRO, 3ASubE cells expressing WT CXCR2 exhibit only ~50% reduction in the total receptor detected by Western blot, suggesting that either only a percentage of the receptors that bind ligand undergo degradation after sequestration or, alternatively, newly translated CXCR2 rapidly replenishes the receptor pool. A recent study of the N-formyl peptide receptor demonstrates a similar dynamic state of receptor sequestration, counterbalanced by the reappearance of receptors at the membrane (13).

3ASubE cells expressing wild type and mutant CXCR2 exhibit only subtle differences in the time course for desensitization or receptor sequestration produced by IL-8 and MGSA/GRO. However, larger differences in IL-8- versus MGSA/GRO-induced calcium signaling in 293 cells expressing transfected CXCR2 were recently observed by Damaj et al. (21), who suggested that MGSA/GRO elicits a stronger influx of Ca2+ than does IL-8. Differences in IL-8 versus MGSA/GRO induction of sequestration of CXCR2 were observed by Prado et al. in transfected CHO cells (11). The basis for the different results between these two studies and our study is unclear but could reflect differences in the specific activity or potency of the ligand preparations or differences in the manner in which the various cell types process the receptors. More in keeping with our own findings, Ahuja et al. (22, 23) reported similar profiles of calcium mobilization for IL-8 and MGSA/GRO proteins in stably transfected 293 cells expressing CXCR2, although MGSA/GRO was unable to totally desensitize receptors to a second weaker response to IL-8.

The beta -adrenergic receptors are phosphorylated along the carboxyl tail by beta -adrenergic receptor kinase and then assume a conformation that allows association with an arrestin (14). This association with arrestin is thought to be necessary for both desensitization and for sequestration. In the case of the beta 2-adrenergic receptor, tyrosine phosphorylation of Tyr-326 is involved in facilitation of sequestration of this receptor (14). We observe no tyrosine phosphorylation of CXCR2 in response to ligand or phorbol-ester stimulation. While some investigators have reported that sequestration is not dependent upon phosphorylation, others have shown that overexpression of beta -adrenergic receptor kinase-1 can facilitate the sequestration of the M2-muscarinic receptor. Moreover, for the M2 receptor, desensitization has been shown to proceed in the absence of sequestration (15, 16). A number of seven-transmembrane G protein-coupled receptors show loss of both phosphorylation and sequestration when the carboxyl-terminal domain is deleted (17-19). Our studies on CXCR2 phosphorylation, desensitization, and sequestration demonstrate that the loss of four specific serine residues involved in ligand-stimulated receptor phosphorylation results in markedly diminished receptor desensitization and loss of receptor sequestration but no loss of ligand-induced chemotaxis. However, we are unable to assign significance to any one specific phosphorylation site regarding a role for desensitization or sequestration. Multiple sites appear to be phosphorylated. A similar cluster of serine and threonine residues regulates CXCR1 desensitization in the RBL-2H3 leukemia cell line (11). However, it is important to note that desensitization does not always require receptor phosphorylation. Richardson et al. (20) have recently shown that activation of an epitope-tagged fMLP receptor can cross-desensitize and cross-phosphorylate both the epitope-tagged C5a receptor and CXCR1. C5a and IL-8 also cross-desensitized the epitope-tagged fMLP receptor based upon Ca2+ mobilization and phosphoinositide hydrolysis, but this is not accompanied by phosphorylation of the epitope-tagged fMLP receptor. Richardson et al. (20) concluded that these data indicate that activation of phospholipase C, independent of receptor G protein coupling, might be involved in cross-desensitization in the absence of receptor phosphorylation (20).

We have observed only serine phosphorylation of CXCR2 (4, 5). Moreover, phosphoamino acid analysis of the mutant forms of CXCR2 studied here revealed only serine phosphorylation (data not shown). Truncation and serine mutants of CXCR2 that exhibited a loss of ligand-induced CXCR2 phosphorylation also exhibited a loss of TPA-induced CXCR2 phosphorylation. Thus, in 3ASubE cells CXCR2 is regulated very differently from CXCR1 in RBL-2H3 leukemia cells, where threonine phosphorylation may also be important, and phorbol-ester regulation of receptor phosphorylation appears to differ from that initiated by ligand (11). Like the CXCR1, phosphorylation of CXCR2 along the carboxyl-terminal domain appears to be important in the desensitization process, and loss of amino acid residues involved in this phosphorylation results in diminution of the receptor desensitization as well as receptor sequestration in response to ligand. Moreover, these two receptors appear to exhibit differences in the time course of sequestration and recycling (3). These events are likely to be important in the regulation of the inflammatory response, where an acute response to injury is required to quickly turn on and gradually shut off in an environmental milieu where excess ligand may persist for some time.


FOOTNOTES

*   This research was supported by National Institutes of Health Grants CA34590 and 5P30 AR41943, a Department of Veterans Affairs Merit and Associate Career Scientist Award (to A. R.), and a grant from the Medical Research Council of Canada (to S. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
par    To whom correspondence should be addressed. Tel.: 615-343-7777; Fax: 615-343-4539.
1   The abbreviations used are: CXC chemokine, chemokine with the first two amino acids separated by an intervening amino acid; 3A, CXCR2 mutant with serine to alanine substitutions at positions 346, 347, and 348; 4A, CXCR2 mutant with serine to alanine substitutions at positions 342, 346, 347, and 348; 342T, CXCR2 truncated at the Ser-342 by placing a stop codon at Ser-342; 331T CXCR2 truncated at Ser-331 by placement of a stop codon in place of Ser; 352T, CXCR2 truncated at Ser-352 by placing a stop codon at Ser-352; 293 cells, human embryonic kidney cell line; 293T2, human embryonic kidney 293 cells expressing transfected human CXCR2; CC chemokines, chemokines with the first two cysteines positioned side-by-side; CMV cytomegalovirus; CXCR1, receptor for CXC chemokines formerly referred to as IL-8 receptor A; CXCR2, receptor for CXC chemokines formerly defined as IL-8 receptor B; C5a, complement fragment 5a; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; fMLP, N-formyl-methionyl-leucyl-phenylalanine; FURA-2 fluorescence indicator for free calcium; IL-8, interleukin-8; MGSA/GRO, melanoma growth-stimulatory activity/growth-related protein; PBS phosphate-buffered saline; TPA, 12-O-tetradecanoylphorbol-13-acetate; WT, wild type.

ACKNOWLEDGEMENTS

We are grateful to Rita Perry Davis and Hamid Haghnegahdar for excellent technical assistance, to Judithann M. Lee for assistance with the cell culture work throughout the calcium studies, to Paul Matrisian for help with the mutant receptor constructs, to Brandon Mosely for excellent help with the photography, and to Rebecca Shattuck-Brandt and Lee Limbird for helpful discussions.


REFERENCES

  1. Richmond, A., and Shattuck, R. L. (1996) in Chemoattractant Ligands and Their Receptors (Horuk, R., ed), pp. 87-124, CRC Press, Inc., New York
  2. Samanta, A. K., Oppenheim, J. J., and Matsushima, K. (1990) J. Biol. Chem. 265, 183-189 [Abstract/Free Full Text]
  3. Chuntharapai, A., and Kim, K. J. (1995) J. Immunol. 155, 2587-2594 [Abstract]
  4. Mueller, S. G., Schraw, W. P., and Richmond, A. (1994) J. Biol. Chem. 269, 1973-1980 [Abstract/Free Full Text]
  5. Mueller, S. G., Schraw, W. P., and Richmond, A. (1995) J. Biol. Chem. 270, 10439-10448 [Abstract/Free Full Text]
  6. Pitcher, J., Lohse, M. J., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1992) Biochemistry 31, 3193-3197 [Medline] [Order article via Infotrieve]
  7. Pei, G., Samama, P., Lohse, M., Wang, M., Codina, J., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2699-2702 [Abstract]
  8. Ferguson, S. S. G., Menard, L., Barak, L. S., Koch, W. J., Colapietro, A.-M., and Caron, M. G. (1995) J. Biol. Chem. 270, 24782-24789 [Abstract/Free Full Text]
  9. Ben-Baruch, A., Xu, L., Young, P. R., Bengali, K., Oppenheim, J. J., and Wang, J. M. (1995) J. Biol. Chem. 270, 22123-22128 [Abstract/Free Full Text]
  10. Franci, C., Gosling, J., Tsou, C-L., Coughlin, S. R., and Charo, I. F. (1996) J. Immunol. 157, 5606-5612 [Abstract]
  11. Richardson, R. M., DuBose, R. A., Ali, H., Tomhave, E. D., Haribabu, D., and Snyderman, R. (1995) Biochemistry 34, 14193-14201 [Medline] [Order article via Infotrieve]
  12. Prado, G. N., Suzuki, H., Wilkinson, N., Cousins, B., and Navarro, J. (1996) J. Biol. Chem. 271, 19186-19190 [Abstract/Free Full Text]
  13. Hoffman, J. F., Linderman, J. J., and Omann, G. M. (1996) J. Biol. Chem. 271, 18394-18404 [Abstract/Free Full Text]
  14. Ferguson, S. S. G., Downey, W. E., III, Colapietro, A-M., Barak, L. S, Menard, L., and Caron, M. G. (1996) Science 271, 363-366 [Abstract]
  15. Yu, S. S., Lefkowitz, R. J., and Hausdorff, W. P. (1993) J. Biol. Chem. 268, 337-341 [Abstract/Free Full Text]
  16. Barak, L. S., Tiberi, M., Freedman, N. J., Kwatra, M. M., Lefkowitz, R. J., and Caron, M. G. (1994) J. Biol. Chem. 269, 2790-2795 [Abstract/Free Full Text]
  17. Lattion, A.-L., Diviani, D., and Cotecchia, S. (1994) J. Biol. Chem. 269, 22887-22893 [Abstract/Free Full Text]
  18. Huang, Z., Chen, Y., and Nissenson, R. A. (1995) J. Biol. Chem. 270, 151-156 [Abstract/Free Full Text]
  19. Thomas, W. G., Thekkumkara, T. J., Motel, T. J., and Baker, K. M. (1995) J. Biol. Chem. 270, 207-213 [Abstract/Free Full Text]
  20. Richardson, R. M., Ali, H., Tomhave, E. D., Haribabu, B., and Snyderman, R. (1995) J. Biol. Chem. 270, 27829-27833 [Abstract/Free Full Text]
  21. Damaj, B. B., McColl, S. R., Neote, K., Hebert, C. A., and Naccache, P. H. (1996) J. Biol. Chem. 271, 20540-20544 [Abstract/Free Full Text]
  22. Ahuja, S. K., Lee, J. C., and Murphy, P. M. (1996) J. Biol. Chem. 271, 225-232 [Abstract/Free Full Text]
  23. Ahuja, S. K., and Murphy, P. M. (1996) J. Biol. Chem. 271, 20545-20550 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.